Boehringer Ingelheim GmbH / Amgen Inc. (Fremont manufacturing facility)

Biologics Contract Manufacturing (Mammalian Cell Culture)

Disease Overview

Mammalian cell culture is the dominant expression system for monoclonal antibodies and complex glycoproteins because mammalian cells perform the post-translational modifications required for safety and efficacy. Contract biologics manufacturing meets demand from emerging biotechs without internal capacity and from large pharma flexing capacity around clinical-to-commercial transitions. The Fremont site originally came to Amgen via the 2006 Abgenix acquisition.

Competitive Landscape

In 2011 the biologics CMO landscape was concentrated among a handful of established mammalian-capable players: Lonza (Switzerland/UK/Singapore), Boehringer Ingelheim Biopharmaceuticals (Germany/Austria), Celltrion (Korea), Catalent and DSM (cell culture services). Samsung Biologics had only just been founded; WuXi Biologics did not yet exist as a standalone entity. Boehringer Ingelheim acquiring Amgen's Fremont site for an undisclosed price gave it 200,000+ sq ft of mammalian capacity, 300+ trained staff and an immediate US West Coast presence — its first US biopharma CMO site, complementing its German and Austrian facilities. For Amgen, the divestiture monetized excess capacity inherited from Abgenix in 2006 and let it focus internal manufacturing on its own branded biologics. Industry analysts framed the deal as accretive to BI's CMO franchise at a time when emerging biotechs were demanding US-based mammalian capacity and biosimilar manufacturers were scaling up; closing March 24, 2011, the transaction made BI the largest US West Coast mammalian CMO overnight. The deal foreshadowed the broader biologics CMO build-out — the global biologics CDMO market reached ~$31.9B by 2024, with mammalian platforms holding ~57% share.